259 related articles for article (PubMed ID: 31100478)
1. p66Shc protein through a redox mechanism enhances the progression of prostate cancer cells towards castration-resistance.
Miller DR; Ingersoll MA; Chatterjee A; Baker B; Shrishrimal S; Kosmacek EA; Zhu Y; Cheng PW; Oberley-Deegan RE; Lin MF
Free Radic Biol Med; 2019 Aug; 139():24-34. PubMed ID: 31100478
[TBL] [Abstract][Full Text] [Related]
2. Dynamics of antioxidant heme oxygenase-1 and pro-oxidant p66Shc in promoting advanced prostate cancer progression.
Miller DR; Ingersoll MA; Chou YW; Kosmacek EA; Oberley-Deegan RE; Lin MF
Free Radic Biol Med; 2022 Nov; 193(Pt 1):274-291. PubMed ID: 36265795
[TBL] [Abstract][Full Text] [Related]
3. p66Shc regulates migration of castration-resistant prostate cancer cells.
Ingersoll MA; Chou YW; Lin JS; Yuan TC; Miller DR; Xie Y; Tu Y; Oberley-Deegan RE; Batra SK; Lin MF
Cell Signal; 2018 Jun; 46():1-14. PubMed ID: 29462661
[TBL] [Abstract][Full Text] [Related]
4. ErbB-2 signaling plays a critical role in regulating androgen-sensitive and castration-resistant androgen receptor-positive prostate cancer cells.
Muniyan S; Chen SJ; Lin FF; Wang Z; Mehta PP; Batra SK; Lin MF
Cell Signal; 2015 Nov; 27(11):2261-71. PubMed ID: 26257301
[TBL] [Abstract][Full Text] [Related]
5. Galectin-3 Is Implicated in Tumor Progression and Resistance to Anti-androgen Drug Through Regulation of Androgen Receptor Signaling in Prostate Cancer.
Dondoo TO; Fukumori T; Daizumoto K; Fukawa T; Kohzuki M; Kowada M; Kusuhara Y; Mori H; Nakatsuji H; Takahashi M; Kanayama HO
Anticancer Res; 2017 Jan; 37(1):125-134. PubMed ID: 28011482
[TBL] [Abstract][Full Text] [Related]
6. Role of protein S in castration-resistant prostate cancer-like cells.
Ning P; Zhong JG; Jiang F; Zhang Y; Zhao J; Tian F; Li W
Endocr Relat Cancer; 2016 Aug; 23(8):595-607. PubMed ID: 27342144
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological inhibition of androgen receptor expression induces cell death in prostate cancer cells.
Song IS; Jeong YJ; Kim J; Seo KH; Baek NI; Kim Y; Kim CS; Jang SW
Cell Mol Life Sci; 2020 Nov; 77(22):4663-4673. PubMed ID: 31894360
[TBL] [Abstract][Full Text] [Related]
8. Reactive oxygen species induced by p66Shc longevity protein mediate nongenomic androgen action via tyrosine phosphorylation signaling to enhance tumorigenicity of prostate cancer cells.
Veeramani S; Chou YW; Lin FC; Muniyan S; Lin FF; Kumar S; Xie Y; Lele SM; Tu Y; Lin MF
Free Radic Biol Med; 2012 Jul; 53(1):95-108. PubMed ID: 22561705
[TBL] [Abstract][Full Text] [Related]
9. TXNDC9 regulates oxidative stress-induced androgen receptor signaling to promote prostate cancer progression.
Feng T; Zhao R; Sun F; Lu Q; Wang X; Hu J; Wang S; Gao L; Zhou Q; Xiong X; Dong X; Wang L; Han B
Oncogene; 2020 Jan; 39(2):356-367. PubMed ID: 31477836
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of LSD1 by Pargyline inhibited process of EMT and delayed progression of prostate cancer in vivo.
Wang M; Liu X; Guo J; Weng X; Jiang G; Wang Z; He L
Biochem Biophys Res Commun; 2015 Nov; 467(2):310-5. PubMed ID: 26435505
[TBL] [Abstract][Full Text] [Related]
11. Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures.
Chattopadhyay I; Wang J; Qin M; Gao L; Holtz R; Vessella RL; Leach RW; Gelman IH
Oncotarget; 2017 Feb; 8(6):10324-10347. PubMed ID: 28055971
[TBL] [Abstract][Full Text] [Related]
12. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
13. RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.
Thomas-Jardin SE; Dahl H; Kanchwala MS; Ha F; Jacob J; Soundharrajan R; Bautista M; Nawas AF; Robichaux D; Mistry R; Anunobi V; Xing C; Delk NA
Prostate; 2020 Feb; 80(2):133-145. PubMed ID: 31730277
[TBL] [Abstract][Full Text] [Related]
14. CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.
Ishikura N; Kawata H; Nishimoto A; Nakamura R; Tsunenari T; Watanabe M; Tachibana K; Shiraishi T; Yoshino H; Honma A; Emura T; Ohta M; Nakagawa T; Houjo T; Corey E; Vessella RL; Aoki Y; Sato H
Int J Oncol; 2015 Apr; 46(4):1560-72. PubMed ID: 25634071
[TBL] [Abstract][Full Text] [Related]
15. Androgen-independent LNCaP cells are a subline of LNCaP cells with a more aggressive phenotype and androgen suppresses their growth by inducing cell cycle arrest at the G1 phase.
Yu P; Duan X; Cheng Y; Liu C; Chen Y; Liu W; Yin B; Wang X; Tao Z
Int J Mol Med; 2017 Nov; 40(5):1426-1434. PubMed ID: 28901378
[TBL] [Abstract][Full Text] [Related]
16. 20(S)-protopanaxadiol inhibition of progression and growth of castration-resistant prostate cancer.
Cao B; Qi Y; Yang Y; Liu X; Xu D; Guo W; Zhan Y; Xiong Z; Zhang A; Wang AR; Fu X; Zhang H; Zhao L; Gu J; Dong Y
PLoS One; 2014; 9(11):e111201. PubMed ID: 25375370
[TBL] [Abstract][Full Text] [Related]
17. PDIA2 has a dual function in promoting androgen deprivation therapy induced venous thrombosis events and castrate resistant prostate cancer progression.
Li Y; Lv L; Ye M; Xie N; Fazli L; Wang Y; Wang W; Yang S; Ni Q; Chen J; Guo X; Zhao Y; Xue G; Sha J; Dong X; Zhang L
Oncogene; 2024 May; 43(21):1631-1643. PubMed ID: 38589675
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.
Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X
J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587
[TBL] [Abstract][Full Text] [Related]
19. FOXM1 promotes the progression of prostate cancer by regulating PSA gene transcription.
Liu Y; Liu Y; Yuan B; Yin L; Peng Y; Yu X; Zhou W; Gong Z; Liu J; He L; Li X
Oncotarget; 2017 Mar; 8(10):17027-17037. PubMed ID: 28199985
[TBL] [Abstract][Full Text] [Related]
20. miR-30a inhibits androgen-independent growth of prostate cancer via targeting MYBL2, FOXD1, and SOX4.
Li X; Jiao M; Hu J; Qi M; Zhang J; Zhao M; Liu H; Xiong X; Dong X; Han B
Prostate; 2020 Jun; 80(9):674-686. PubMed ID: 32294305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
